# Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct07040098/  
OnCo record `nct07040098` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sintilimab and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.

## Summary

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07040098 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 228 participants, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sintilimab; Short-course radiotherapy; Long-course concurrent chemoradiotherapy; CAPOX. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Rate of complete response. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal adenocarcinoma with immunohistochemical results indicating pMMR (proficient mismatch repair) or genetic testing confirming MSS (microsatellite stability);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: STELLARIII
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07040098
- Phase: 2
- Setting: A Prospective, Multicenter, Randomized Clinical Trial of Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer (STELLARIII)
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 228

## Sources

- ClinicalTrials.gov NCT07040098: https://clinicaltrials.gov/study/NCT07040098

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07040098.json